20970 Allo Homepage Banner

Join the Allogeneic Cell Therapies Summit to Innovate an Off-the-Shelf Future!

Patient-specific cell therapies have changed the face of cancer treatment, but with price points sky high and laborious manufacturing processes, this cure is out of reach for many patients.

The 3rd annual Allogeneic Cell Therapies Summit was once again the only industry-focused meeting dedicated to accelerating the clinical translation of allogeneic cell therapy, to provide an affordable and accessible treatment for patients globally.

With 3 tracks of unrivalled content spanning translation, manufacturing and commercialization, topics covered next generation gene engineering to overcome rejection, improve persistence through arming and dosing, and optimize CMC and quality control to achieve long term stability at high yields and high efficacy.

325+ senior level drug developers collaborated online to achieve the holy grail of allogeneic therapies, improving their competitive intelligence and capitalizing on the simplified logistics, time to delivery and reduced cost of off-the-shelf approaches.

"High level and relevant exchange of experience in a very comfortable and friendly atmosphere with great people."

PHD Candidate, Charité Universitätsmedizin Berlin

"Very informative summit with lots of great material, knowledgeable and engaging speakers and overall a fantastic experience."

Non-clinical Safety Lead, Johnson & Johnson

"This was a very nice event. The focus on Allogeneic was really good and this summit provided an opportunity to have a more holistic view of the field and its potential. Very well done!"

Chief Operations Officer, Celyad

PARTNERS: